Key result
Endomyocardial biopsy remains an important diagnostic tool for evaluating unexplained cardiomyopathy and identifying potentially treatable conditions like Anderson-Fabry disease.
Answers are grounded in this paper and cite their sources.
Endomyocardial biopsy remains an important diagnostic tool for identifying Anderson-Fabry disease and other secondary myocardial involvements in patients with unexplained cardiomyopathy.
To the Editor:Sachdev et al 1 describe the utility of plasma ␣-galactosidase for diagnosing Anderson-Fabry disease.As the authors emphasize, this disease is not particularly common, but it may be potentially treatable or stabilized with recent advances in treatment.A recent study 2 documented stabilization of cardiac disease using galactose infusions in a patient with Fabry's disease who had been a transplant candidate.Fabry's disease may also be diagnosed using endomyocardial biopsy.Fabry's disease may be encountered in individuals being examined because of unexplained left ventricular hypertrophy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and dilated cardiomyopathy.3 In the investigation of patients with unexplained cardiomyopathy or ventricular hypertrophy, the pathologist responsible for assessing the biopsy specimens and the clinician must consider the possibility of Fabry's disease.Fabry's disease has a characteristic electron microscopic appearance, with lysosomal lamellar bodies, and thus requires special processing and fixation for this evaluation.The biopsy specimens may also be easily evaluated for the presence of myocyte iron and interstitial amyloid.Hemochromatosis and amyloidosis enter into the differential diagnosis of disorders causing systolic and diastolic dysfunction.Variants of Fabry's confined to the heart have been described.3,4 Cardiomyopathy in heterozygote individuals has been detected using endomyocardial biopsy.5 As Sachdev et al 1 note, biopsy evaluation may be important because the female heterozygotes may be difficult to diagnose biochemically because of intermediate levels of enzyme activity overlapping with that of normal individuals.1 Use of endomyocardial biopsy is declining, except in the evaluation of post-transplant rejection, and it may be forgotten as an important tool for diagnosis.In addition to the assessment of transplant rejection, these biopsies may be evaluated for myocarditis, cardiomyopathy, drug toxicity, cardiac neoplastic involvement, and secondary myocardial involvement by systemic diseases, including hemochromatosis, amyloidosis, and storage diseases.Some of these disorders might be diagnosed, treated, and cured or controlled.
No takes yet. Share an insight, caveat, or question.
John P. Veinot (2002) conducted a letter in Anderson-Fabry disease / Cardiomyopathy. Endomyocardial biopsy was evaluated. Endomyocardial biopsy remains an important diagnostic tool for evaluating unexplained cardiomyopathy and identifying potentially treatable conditions like Anderson-Fabry disease.
Synapse has enriched 10 related papers. Consider them for comparative context: